Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of capecitabine, sorafenib, and sunitinib-induced hand-foot syndrome on fingerprints
NL-OMON28548Recruiting
- Sponsor
- Erasmus MC
- Start
- Aug 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of capecitabine, sorafenib and sunitinib in cancer (3 cohorts), sponsored by Erasmus MC. Started Aug 2013; status: recruiting.
02
Drugs
capecitabinesorafenibsunitinib
03
Conditions
cancer
Beyond the preview
Go deeper on NL-OMON28548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28548.